{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:11:47Z","timestamp":1779163907794,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 106-3114-Y404-002; 107-0324-01-19-13"],"award-info":[{"award-number":["MOST 106-3114-Y404-002; 107-0324-01-19-13"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Influenza vaccine manufacturers traditionally use egg-derived candidate vaccine viruses (CVVs) to produce high-yield influenza viruses for seasonal or pandemic vaccines; however, these egg-derived CVVs need an adaptation process for the virus to grow in mammalian cells. The low yields of cell-based manufacturing systems using egg-derived CVVs remain an unsolved issue. This study aimed to develop high-growth cell-derived CVVs for MDCK cell-based vaccine manufacturing platforms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four H7N9 CVVs were generated in characterized Vero and adherent MDCK (aMDCK) cells. Furthermore, reassortant viruses were amplified in adherent MDCK (aMDCK) cells with certification, and their growth characteristics were detected in aMDCK cells and new suspension MDCK (sMDCK) cells. Finally, the plaque-forming ability, biosafety, and immunogenicity of H7N9 reassortant viruses were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The HA titers of these CVVs produced in proprietary suspension MDCK (sMDCK) cells and chicken embryos were 2- to 8-fold higher than those in aMDCK cells. All H7N9 CVVs showed attenuated characteristics by trypsin-dependent plaque assay and chicken embryo lethality test. The alum-adjuvanted NHRI-RG5 (derived from the fifth wave H7N9 virus A\/Guangdong\/SP440\/2017) vaccine had the highest immunogenicity and cross-reactivity among the four H7N9 CVVs. Finally, we found that AddaVax adjuvant improved the cross-reactivity of low pathogenic H7N9 virus against highly pathogenic H7N9 viruses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study indicates that cell-derived H7N9 CVVs possessed high growth rate in new sMDCK cells and low pathogenicity in chicken embryo, and that CVVs generated by this platform are also suitable for both cell- and egg-based prepandemic vaccine production.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12929-020-00645-y","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T09:03:28Z","timestamp":1585818208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells"],"prefix":"10.1186","volume":"27","author":[{"given":"Tsai-Teng","family":"Tzeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Chuan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Yi","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-I","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Tsan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Chou","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Shi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Yung-Chih","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"645_CR1","unstructured":"Food and Agriculture Organization. http:\/\/www.fao.org\/ag\/againfo\/programmes\/en\/empres\/h7n9\/situation_update.html. Accessed 27 Jun 2019."},{"key":"645_CR2","doi-asserted-by":"crossref","unstructured":"Zhu W, Zhou J, Li Z, Yang L, Li X, Huang W, et al. Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017. Euro Surveill. 2017;22(19):30533.","DOI":"10.2807\/1560-7917.ES.2017.22.19.30533"},{"issue":"3","key":"645_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jfma.2017.02.011","volume":"116","author":"JR Yang","year":"2017","unstructured":"Yang JR, Liu MT. Human infection caused by an avian influenza a (H7N9) virus with a polybasic cleavage site in Taiwan, 2017. J Formos Med Assoc. 2017;116(3):210\u20132.","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"645_CR4","volume":"2","author":"X Liu","year":"2013","unstructured":"Liu X, Li T, Zheng Y, Wong KW, Lu S, Lu H. Poor responses to oseltamivir treatment in a patient with influenza a (H7N9) virus infection. Emerg Microbes Infect. 2013;2(5):e27.","journal-title":"Emerg Microbes Infect"},{"issue":"9885","key":"645_CR5","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(13)61125-3","volume":"381","author":"Y Hu","year":"2013","unstructured":"Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. Association between adverse clinical outcome in human disease caused by novel influenza a H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381(9885):2273\u20139.","journal-title":"Lancet."},{"issue":"3","key":"645_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.tim.2011.12.002","volume":"20","author":"MS Lee","year":"2012","unstructured":"Lee MS, Hu AY. A cell-based backup to speed up pandemic influenza vaccine production. Trends Microbiol. 2012;20(3):103\u20135.","journal-title":"Trends Microbiol"},{"issue":"5","key":"645_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","volume":"11","author":"NR Hegde","year":"2015","unstructured":"Hegde NR. Cell culture-based influenza vaccines: a necessary and indispensable investment for the future. Hum Vaccin Immunother. 2015;11(5):1223\u201334.","journal-title":"Hum Vaccin Immunother"},{"key":"645_CR8","doi-asserted-by":"crossref","unstructured":"Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines. 2018;6(2):19-31.","DOI":"10.3390\/vaccines6020019"},{"issue":"21","key":"645_CR9","doi-asserted-by":"publisher","first-page":"10502","DOI":"10.1128\/JVI.00970-08","volume":"82","author":"S Murakami","year":"2008","unstructured":"Murakami S, Horimoto T, Mai le Q, Nidom CA, Chen H, Muramoto Y, et al. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J Virol. 2008;82(21):10502\u20139.","journal-title":"J Virol"},{"issue":"10","key":"645_CR10","doi-asserted-by":"publisher","first-page":"e24057","DOI":"10.1371\/journal.pone.0024057","volume":"6","author":"YF Tseng","year":"2011","unstructured":"Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, et al. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One. 2011;6(10):e24057.","journal-title":"PLoS One"},{"issue":"1","key":"645_CR11","doi-asserted-by":"publisher","first-page":"e14578","DOI":"10.1371\/journal.pone.0014578","volume":"6","author":"AY Hu","year":"2011","unstructured":"Hu AY, Tseng YF, Weng TC, Liao CC, Wu J, Chou AH, et al. Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One. 2011;6(1):e14578.","journal-title":"PLoS One"},{"issue":"3","key":"645_CR12","doi-asserted-by":"publisher","first-page":"e0120793","DOI":"10.1371\/journal.pone.0120793","volume":"10","author":"MY Chia","year":"2015","unstructured":"Chia MY, Hu AY, Tseng YF, Weng TC, Lai CC, Lin JY, et al. Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets. PLoS One. 2015;10(3):e0120793.","journal-title":"PLoS One"},{"key":"645_CR13","doi-asserted-by":"publisher","first-page":"8148","DOI":"10.1038\/ncomms9148","volume":"6","author":"J Ping","year":"2015","unstructured":"Ping J, Lopes TJS, Nidom CA, Ghedin E, Macken CA, Fitch A, et al. Development of high-yield influenza a virus vaccine viruses. Nat Commun. 2015;6:8148.","journal-title":"Nat Commun"},{"issue":"6","key":"645_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4014\/jmb.1712.12007","volume":"28","author":"EH Kim","year":"2018","unstructured":"Kim EH, Kwon HI, Park SJ, Kim YI, Si YJ, Lee IW, et al. Generation of a high-growth influenza vaccine strain in MDCK cells for vaccine preparedness. J Microbiol Biotechnol. 2018;28(6):997\u20131006.","journal-title":"J Microbiol Biotechnol"},{"issue":"2","key":"645_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.vaccine.2014.11.007","volume":"33","author":"W Hu","year":"2015","unstructured":"Hu W, Zhang H, Han Q, Li L, Chen Y, Xia N, et al. A Vero-cell-adapted vaccine donor strain of influenza a virus generated by serial passages. Vaccine. 2015;33(2):374\u201381.","journal-title":"Vaccine."},{"key":"645_CR16","unstructured":"World Health Organization. https:\/\/www.who.int\/influenza\/vaccines\/virus\/candidates_reagents\/summary_a_h7n9_cvv_20180305.pdf. Accessed 22 Mar 2018."},{"issue":"185","key":"645_CR17","doi-asserted-by":"publisher","first-page":"185ra168","DOI":"10.1126\/scitranslmed.3006368","volume":"5","author":"PR Dormitzer","year":"2013","unstructured":"Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med. 2013;5(185):185ra168.","journal-title":"Sci Transl Med"},{"issue":"1","key":"645_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12985-019-1194-9","volume":"16","author":"J Tang","year":"2019","unstructured":"Tang J, Zhang J, Zhou J, Zhu W, Yang L, Zou S, et al. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts. Virol J. 2019;16(1):87.","journal-title":"Virol J"},{"issue":"12","key":"645_CR19","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s007050170002","volume":"146","author":"E Hoffmann","year":"2001","unstructured":"Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza a viruses. Arch Virol. 2001;146(12):2275\u201389.","journal-title":"Arch Virol"},{"issue":"11","key":"645_CR20","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1073\/pnas.100133697","volume":"97","author":"E Hoffmann","year":"2000","unstructured":"Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza a virus from eight plasmids. Proc Natl Acad Sci U S A. 2000;97(11):6108\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"645_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ REED","year":"1938","unstructured":"REED LJ, MUENCH H. A simple method of estimating fifty percent endpoints. Am J Epidemiol. 1938;27(3):493\u20137.","journal-title":"Am J Epidemiol"},{"issue":"22","key":"645_CR22","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.vaccine.2017.03.016","volume":"36","author":"YF Tseng","year":"2018","unstructured":"Tseng YF, Weng TC, Lai CC, Chen PL, Lee MS, Hu AY. A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography. Vaccine. 2018;36(22):3146\u201352.","journal-title":"Vaccine."},{"key":"645_CR23","unstructured":"World Health Organization. https:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_979_Annex_5.pdf. Accessed 5 Jun 2019."},{"key":"645_CR24","unstructured":"World Health Organization. https:\/\/www.who.int\/csr\/resources\/publications\/influenza\/whocdscsrncs20025rev.pdf. Accessed 1 Mar 2017."},{"issue":"1","key":"645_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1128\/CDLI.5.1.114-117.1998","volume":"5","author":"CA Benne","year":"1998","unstructured":"Benne CA, Kroon FP, Harmsen M, Tavares L, Kraaijeveld CA, De Jong JC. Comparison of neutralizing and hemagglutination-inhibiting antibody responses to influenza a virus vaccination of human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol. 1998;5(1):114\u20137.","journal-title":"Clin Diagn Lab Immunol"},{"key":"645_CR26","unstructured":"World Health Organization. https:\/\/www.who.int\/influenza\/resources\/documents\/influenza_vaccine-virus_selection\/en\/. Accessed 19 Nov 2018."},{"issue":"6","key":"645_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1750-2659.2009.00104.x","volume":"3","author":"J Dong","year":"2009","unstructured":"Dong J, Matsuoka Y, Maines TR, Swayne DE, O'Neill E, Davis CT, et al. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respir Viruses. 2009;3(6):287\u201395.","journal-title":"Influenza Other Respir Viruses"},{"issue":"35","key":"645_CR28","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1016\/j.vaccine.2014.06.043","volume":"32","author":"CY Wu","year":"2014","unstructured":"Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, et al. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine. 2014;32(35):4485\u201394.","journal-title":"Vaccine."},{"key":"645_CR29","unstructured":"World Health Organization. https:\/\/www.who.int\/csr\/disease\/swineflu\/notes\/h1n1_vaccine_20090806\/en\/. Accessed 17 Oct 2018."},{"key":"645_CR30","unstructured":"Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/flu\/avianflu\/candidate-vaccine-virus.htm. Accessed 17 Jan 2018."},{"issue":"35","key":"645_CR31","doi-asserted-by":"publisher","first-page":"14802","DOI":"10.1073\/pnas.0905912106","volume":"106","author":"C Chu","year":"2009","unstructured":"Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J. Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci U S A. 2009;106(35):14802\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"645_CR32","doi-asserted-by":"publisher","first-page":"e0141686","DOI":"10.1371\/journal.pone.0141686","volume":"10","author":"D Huang","year":"2015","unstructured":"Huang D, Peng WJ, Ye Q, Liu XP, Zhao L, Fan L, et al. Serum-free suspension culture of MDCK cells for production of influenza H1N1 vaccines. PLoS One. 2015;10(11):e0141686.","journal-title":"PLoS One"},{"issue":"38","key":"645_CR33","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","volume":"28","author":"V Lohr","year":"2010","unstructured":"Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine. 2010;28(38):6256\u201364.","journal-title":"Vaccine."},{"issue":"12","key":"645_CR34","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1128\/JVI.00100-14","volume":"88","author":"Z Chen","year":"2014","unstructured":"Chen Z, Baz M, Lu J, Paskel M, Santos C, Subbarao K, et al. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol. 2014;88(12):7016\u201323.","journal-title":"J Virol"},{"issue":"3","key":"645_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.vaccine.2015.11.050","volume":"34","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Shirakura M, Suzuki Y, Naito T, Fujisaki S, Tashiro M, et al. Development of a high-yield reassortant influenza vaccine virus derived from the a\/Anhui\/1\/2013 (H7N9) strain. Vaccine. 2016;34(3):328\u201333.","journal-title":"Vaccine."},{"key":"645_CR36","doi-asserted-by":"crossref","unstructured":"Li X, Gao Y, Ye Z. A Single Amino Acid Substitution at Residue 218 of 786 Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate 787 Vaccine Viruses. J Virol. 2019;93(19):e00570-19.","DOI":"10.1128\/JVI.00570-19"},{"issue":"43","key":"645_CR37","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1016\/j.vaccine.2019.08.064","volume":"37","author":"K Nakamura","year":"2019","unstructured":"Nakamura K, Harada Y, Takahashi H, Trusheim H, Bernhard R, Hamamoto I, et al. Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus. Vaccine. 2019;37(43):6526\u201334.","journal-title":"Vaccine."},{"key":"645_CR38","unstructured":"World Health Organization. https:\/\/www.who.int\/biologicals\/BIOSAFETY_RISK_ASSESSMENT_21_MAY_2013.pdf. Accessed 17 Jan 2018."},{"key":"645_CR39","unstructured":"World Health Organization. https:\/\/www.who.int\/influenza\/vaccines\/virus\/201703_zoonotic_vaccinevirusupdate.pdf. Accessed 22 Mar 2018."},{"issue":"10","key":"645_CR40","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3201\/eid2410.180403","volume":"24","author":"M Hatta","year":"2018","unstructured":"Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y. Effectiveness of whole, inactivated, low pathogenicity influenza a(H7N9) vaccine against Antigenically distinct, highly pathogenic H7N9 virus. Emerg Infect Dis. 2018;24(10):1910\u20133.","journal-title":"Emerg Infect Dis"},{"issue":"85","key":"645_CR41","doi-asserted-by":"publisher","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","volume":"3","author":"S Khurana","year":"2011","unstructured":"Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3(85):85ra48.","journal-title":"Sci Transl Med"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12929-020-00645-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T23:11:33Z","timestamp":1617318693000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-020-00645-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1186\/s12929-020-00645-y","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The mouse study protocol was approved by the Institutional Animal Care and Use Committee of NHRI (Number of Permission: NHRI-IACUC-107106-A).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}